Committed to the Prevention of Genetic Disease

About Us

The Previvo team is highly accomplished and is comprised of
a diverse group within the management, medical advisory
board and board of directors.

Management Team

John E. Buster, M.D.

Founder & Chief Medical Officer
Chairman of Scientific Advisory Board

Dr. Buster has nearly four decades experience as a physician, almost entirely focused in the field of Reproductive Endocrinology and Infertility. He is highly experienced in the performance of assisted reproductive technology procedures, medical treatment for infertility and recurrent pregnancy loss, and various reproductive surgical procedures. Due to his extensive background; he is a frequently invited lecturer, consultant and participant in national and international forums. He has served as an officer on Boards and Committees of several professional societies, given expert testimony before Congressional and other government Committees, served as a consultant to numerous healthcare companies, and has been interviewed and featured on national broadcast and print media for many years.

Additionally, and serving as a foundation for Previvo, Dr. Buster directed the research team at UCLA Medical Center that performed history's first embryo transfer from one woman to another resulting in a live birth. In the procedure, an embryo that was just beginning to develop was transferred from one woman in whom it had been conceived by artificial insemination to another woman who gave birth to the infant 38 weeks later. The sperm used in the artificial insemination came from the husband of the woman who bore the baby.

This work established the technical foundation and legal-ethical framework surrounding the clinical use of human oocyte and embryo donation, a mainstream clinical practice, which has evolved over the past 30 years. Building upon Dr. Buster's research and since the initial birth announcement in 1984, well over 200,000 live births resulting from donor embryo transfer have been and continue to be recorded by the Centers for Disease Control (CDC) in the United States to infertile women, who otherwise would not have had children by any other existing method.


Moses Cesario, M.S.

Chief Executive Officer

As CEO of Previvo Genetics, Moses’ vision is to bring clinical tools to physicians that will accelerate the adoption and use of genomic information: “I’m proud to be part of the community that is ushering in the new era of genomic medicine; with Previvo Genetics’ capabilities in hand, our mission is to make PGD (pre-implantation genetic diagnosis) a feasible option for all reproductively active families to achieve the dream of having healthy children”.

Moses' career focus is product development in life sciences in which he has over 20 years of experience in genetic diagnostics, biotechnology and healthcare delivery systems. He has developed multiple successful products in genetics sciences, and spearheaded go-to-market activities for their successful launch in Europe, Asia and the U.S.

Moses’ experience in executive roles spans several leading organizations, including COO of Neomorphic Software (bioinformatics), President of Ramsell Information Technologies, LLC (pharmacy benefits management) and VP and CIO of Affymetrix, Inc. (microarray technology and genomics analysis).

Moses holds degrees from the University of California at Berkeley (B.A.) and Golden Gate University (M.S.). Most recently, he completed the Stanford Executive Program at Stanford University.


Jeffrey M. Prag

Vice President of Marketing & Commercialization

Jeff is Vice President of Marketing and Communications for Previvo Genetics and is responsible for marketing, product branding and digital sales efforts for all of the company’s public affairs, publications, collateral and websites.

A graduate of Northeastern University with concentrations in business, management and accounting, Jeff has worked in such diverse areas as accounting, taxation and corporate finance (for a subsidiary of a Fortune 100 healthcare firm). Prior to joining Previvo Genetics, Jeff was a successful entrepreneur, having been a founder, executive team member and advisor to a number of startup companies taking them from the concept-stage through various levels of development to solid profitability.

Jeff is a committed and energetic leader in multiple community and charitable endeavors including Rotary International and various youth programs. He also provides mentoring and job shadowing opportunities for many high school and college students.

Scientific Advisory Board

Marlane Angle, Ph.D., H.C.L.D.

Dr. Angle has been an embryologist and In Vitro Fertility laboratory director for over 25 years. Moving into the embryology laboratory was the practical synthesis of her graduate studies in embryo and sperm biochemistry/physiology and her NIH postdoctoral work on implantation and fetal developmental biochemistry.

She has directed embryology, andrology and endocrine laboratories in Las Vegas, NV, Seattle, WA and Little Rock, AR. She was among the first group of embryologists to become certified as High Complexity Laboratory Directors by the College of American Pathologists in 1995 and has published frequently in the fertility literature. She is one of the founders and organizers for the Southwest Embryology Summit, has served on multiple boards and committees of various professional societies, is on the guest faculty for the Master’s Program in Embryology at the Eastern Virginia Medical School and has consulted and lectured around the world, particularly in the areas of pH and temperature management in the laboratory, and embryo and oocyte vitrification. She currently lives on her sailboat in Alameda, CA and directs a laboratory in San Francisco, CA.


Steven Nakajima, M.D.

Dr. Nakajima received his medical degree from St. Louis University. He completed an obstetrics and gynecology residency at Loma Linda University and fellowship in Reproductive Endocrinology and Infertility (REI) at the University of Vermont. He completed a second NIH Clinical Associate Physician fellowship in the General Clinical Research Center at the University of Vermont.

He joined the faculty at the University of California, Davis and then was Division Chief of REI at the University of Louisville (UL) for 15 years. He became a faculty member at Stanford in 2014. Dr. Nakajima is board certified in obstetrics and gynecology and REI. From 2008-14, he served as an American Board of Obstetrics and Gynecology REI board member.

He is a current board examiner for subspecialty certification in REI. In 1997, Good Housekeeping magazine named Dr. Nakajima as one of the nation’s “Best Doctors for Women”. His special clinical interests are In Vitro Fertilization, the use of donor eggs for resolving infertility and developing new contraceptive methods for women and men. His research interest is human uterine lavage for preimplantation genetic screening.

Dr. Nakajima is a Past President of the Society for Reproductive Endocrinology and Infertility. Dr. Nakajima has been widely published featured in papers, abstracts, and reviews on various topics related to women’s health. He is the author of the books Contemporary Guide to Contraception, 4th Edition and Clinical Protocols in Pediatric and Adolescent Gynecology.


Camran Nezhat, M.D.

Camran Nezhat, M.D. has been called the father of modern-day operative laparoscopy for introducing the technique of video-assisted endoscopy and proving and publishing that even the most advanced pathologies could be successfully managed by minimally invasive surgery for the first time in history. By doing so, he opened up vistas for endoscopic surgeons all over the world.

Laparoscopic treatment of extensive endometriosis, laparoscopic bowel, bladder, ureter, diaphragm resection and reanastamosis, laparoscopic para aortic node dissection and radical hysterectomy, management of ovarian remnant, laparoscopic-assisted myomectomy, laparoscopic sacral colpopexy, laparoscopic repair of vesico vaginal and recto vaginal fistulas, operative laparoscopy during advanced pregnancy and vaginal cuff dehiscence following laparoscopic hysterectomy all were among some of the procedures reported or performed endoscopically for the first time by Nezhat and his team.

Dr. Nezhat collaborated with renowned robotic pioneers, Ajit Shah and Phil Green at Stanford Research Institute in the 1990’s, during the early phases of research and development of the da Vinci robot.

He is co-author of eight textbooks and author of hundreds of articles.

Recipient of numerous awards worldwide, Dr. Camran Nezhat is Chair of AACF Stanford University School of Medicine, Adjunct Clinical Professor of OB/GYN, Surgery at Stanford University and Clinical Professor of OB/GYN, and University of California at San Francisco.

Board of Directors

Steven K. Buster


Steve is the Chairman of Previvo Genetics and provides a wealth of experience and acumen to the company. He most recently served as President and Chief Executive Officer of Pacific Mercantile Bank, the largest commercial bank headquartered in Orange County, California. With over $1 billion in assets, Pacific Mercantile Bank is a business bank with offices reaching from Beverly Hills to La Jolla in San Diego County and is a publicly traded company on the NASDAQ Exchange.

Prior to his recent appointment at Pacific Mercantile Bank, Buster was President and CEO of Mechanics Bank beginning July, 2004. During his tenure, Mechanics Bank increased annual profit to $29 million in 2007 from $24 million in 2004, and increased shareholder’s equity to $274.5 million in 2007 from $236 million in 2004. Mechanics Bank was one of the rare community banks that performed throughout the “Great Recession”, always earning a respectable return and paying steady continuous quarterly dividends.

Before becoming a community bank President, Buster was with U.S. Trust Company where he was Managing Director responsible for all Western United States banking activities. His 40-year career in banking includes five years in London with First Interstate Bank’s International and Capital Markets Group and five years in Singapore with London-based Standard Chartered Bank. As Group Manager of Standard Chartered Bank, Buster directed the activities of 700 banking officers and 3,000 total staff throughout the Asia Pacific region. He began his banking career with First Interstate Bank, where he served in numerous capacities, including Chief Credit Officer, real estate, corporate banking and as General Manager in London prior to the sale of the wholesale bank to Standard Chartered.

A graduate of the University of Southern California, where he earned his Bachelor of Arts and Master of Business Administration degrees, Buster currently has been serving as a Board Member of the California Banker’s Association and California Independent Bankers (CIB), a not-for-profit trade group serving more than 160 California community banks that is politically active in Sacramento. He also is a board member and serves on the executive committee of the Bay Area Council.

Buster’s background includes service in law enforcement. He committed in 1999 to a two-year assignment as Chief Operating Officer for the District Attorney of Los Angeles County. While in Northern California, he joined the Alameda County Sheriff’s Air Squadron as a qualified Pilot-in-Command and Disaster Service Worker and became the Squadron Captain. He is also the founder and chairman of Bay Area Crime Stoppers.


Dan Janney

Dan is the Managing Partner of Alta Partners. Dan joined Alta at its founding and has over 20 years of successful early stage investing experience in life sciences. His focus on working with exceptional entrepreneurs to create companies around novel insights in biology and new approaches to drug discovery has led to the funding and development of over 35 companies. Prior to Alta, Dan was a senior investment banker at Montgomery Securities where he advised life science companies on over $8 billion of equity and merger transactions.

Dan is currently on the board of directors of several public and private companies, including Alba Therapeutics, Esperion Therapeutics (NASDAQ:ESPR), Evolve Biosystems, Prolacta Bioscience, Sutro Biopharma, and Viveve (OTC:VIVMF). In addition, he led Alta’s investments in Astex Pharmaceuticals (acquired by Supergen), Cellective (acquired by Medimmune), ChemGenex (ASX:CXS acquired by Cephalon), CoTherix (NASDAQ: CTRX acquired by Actellion), Definity Health (acquired by United Health), Dynavax (NASDAQ:DVAX), Endonetics (acquired by Medtronic), Ilex Oncology (NASDAQ:ILXO acquired by Millennium Pharmaceuticals), InterMune (NASDAQ:ITMN acquired by Roche), LJL Biosystems (NASDAQ:LJLB acquired by Molecular Devices), Mako Surgical (NASDAQ:MAKO acquired by Stryker), Neothetics (NASDAQ:NEOT), and Triangle Pharmaceuticals (NASDAQ:VIRS acquired by Gilead).

In 2006 and 2007, Dan was listed in Forbes’ Midas 100 List of Top Tech Investors. He is a member of The President's Council of the J. David Gladstone Institutes and serves on the Board of Regents of Georgetown University. He holds a Bachelor of Arts in History from Georgetown University and a Master of Business Administration from the Anderson School at the University of California, Los Angeles.


Todd Johnson

Todd is a Previvo board member and the Chair of the Compensation Committee.  Todd brings industry experience as a former Chief Executive Officer and President of a medical service company.  He has served in various executive positions with large international corporations and emerging bio-tech companies, managing staffs of over 160 personnel and revenue exceeding $500M.

Prior to his corporate roles, Todd served in the US Army as a commissioned aviation officer, pilot, and intelligence officer in various parts of the world. Todd holds a BS from the United States Military Academy at West Point, where he was presented with the Superintendent’s Award for Excellence and Achievement.

He earned a MBA from Webster University and was awarded Distinguished Honor Graduate.  Also, Todd graduated from the US Army Flight School at Ft. Rucker, AL with the distinction of Honor Graduate.

Todd is currently pursuing a Juris Doctor (JD) at Denver University Sturm College of Law where he is specializing in Corporate and Commercial Business. Todd has worked as a law clerk with Arckey & Associates, a boutique law firm specializing in employment and business litigation, and is currently with the U.S. Securities and Exchange Commission in the Division of Enforcement.


Erin McGurk

Ms. McGurk was appointed to the Previvo Genetics Board of Directors in 2015. Ms. McGurk is a highly accomplished executive and medical technology entrepreneur. Most recently, Ms. McGurk was the founder, Director, President and CEO of PneumRx, a medical device company in the pulmonary market space. Ms. McGurk successfully navigated PneumRx from a start-up through clinical trials and European commercialization. In early 2015, PneumRX was acquired by BTG, plc, a London based international healthcare company. Ms. McGurk has transitioned into a Consulting role for PneumRx-BTG.

Ms. McGurk was also a founder and served on the Board of Directors for Tenaxis Medical from 2006-2014 (acquired by the Medicines Company in 2014). Tenaxis Medical developed, manufactured and commercialized a surgical sealant. Previously, Ms. McGurk was a founder and Managing Director of Magic Venture Capital, LLC (MVC). MVC was a seed investor in such successful companies as Atrionix (acquired by Johnson & Johnson) and Spinal Concepts (acquired by Abbott Labs), of which Ms. McGurk was a founder. She served on the Board of Directors for both companies and was Chairman of the Board for Vector Medical, another MVC company. Ms. McGurk was a founder, executive board member and Vice President of Technology for Micro Interventional Systems (acquired by Medtronic in 1995).

Prior to MIS, Ms. McGurk held executive positions at Baxter Healthcare, Cordis, Dow Corning Wright and American Medical Electronics. She is an inventor on numerous issued patents and patent publications. She holds a B.S. degree in biological sciences from California State University, Long Beach and an M.S. degree in mechanical engineering (bioengineering) from University of California, San Diego.

Investor Information

Previvo is a development stage company funded by the founders and sophisticated, accredited investors. If you have interest in investing, please click here to contact our CEO, Moses Cesario.